Conserv Bioscience

ConserV is a late-stage vaccine development company focused on advancing safe and effective vaccines that protect against endemic and emergent infectious diseases. We have a pipeline of eight vaccines in pre-clinical and clinical development including broad-spectrum influenza*, broad-spectrum coronavirus, mosquito-borne diseases*, HIV, Hepatitis C, Hepatitis B, Rotavirus and Chagas. ConserV’s USP is the identification of antigens consisting of conserved regions of viral proteins containing a high number of REACTIVE T-cell epitopes with extensive HLA coverage.*Sub-licensed to Imutex Limited, a 51% owned subsidiary. hVIVO Services Limited own 49% of Imutex.